CORE

Patient Information

Core is a double blind, placebo controlled phase 3 study of Akcea-APOCIII-LRX administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). The study will evaluate the efficacy of the agent as compared to placebo in the percent change in fasting triglycerides (TG) from Baseline in a population of patients with fasting triglycerides of >500 mg/dl.

Learn More

Study Contact: cardiovascularresearch@conehealth.com

Principal Investigator(s)

Kenneth Hilty, MD

Clinical Trial Categories

• Cholesterol/Diabetes/Hypertension

Sponsor(s)

Ionis Pharmaceuticals, Inc

Akcea Therapeutics, Inc.